If you suffer from Critical Limb Ischemia and have been told by a physician that you are no longer a candidate for surgical or other interventional treatment, you may be eligible for a clinical study of an investigational treatment for patients with advanced CLI.
The study seeks to determine if treatment with adult stem cells, taken from the patient’s own bone marrow, can improve healing and prevent amputation.
Lifecells, LLC is sponsoring a study to assess the efficacy and safety of ASCT01 (autologous stem cell transplantation) in patients with Critical Limb Ischemia (CLI).
This study is being conducted at:
Kansas City Vascular Foundation (KCV),
North Kansas City, Missouri, United States, 64116.
by Dr. Karl Stark, MD FACS
The title of the study is:
An open-label single arm phase 2 study to assess the efficacy and safety of ASCT01 in Patients with Critical Limb IschemiaRead More
The Clinical Trial is a Phase 2, open-label proof of concept study to assess the efficacy and safety of ASCT01 in Patients with Critical Limb Ischemia (CLI).
The purpose of the study is to assess the efficacy and safety of ASCT01 (autologous stem cell transplantation) prepared from the patient's own bone marrow and delivered by catheter for intra-arterial administration and intra-muscular injections in patients with CLI.READ MORE